Chromodomain-helicase-DNA binding protein 5, 7 and pronecrotic mixed lineage kinase domain-like protein serve as potential prognostic biomarkers in patients with resected pancreatic adenocarcinomas

Crystal S. Seldon; Lauren E. Colbert; William A. Hall; Sarah B. Fisher; David S. Yu; Jerome C. Landry

doi:10.4251/wjgo.v8.i4.358

Chromodomain-helicase-DNA binding protein 5, 7 and pronecrotic mixed lineage kinase domain-like protein serve as potential prognostic biomarkers in patients with resected pancreatic adenocarcinomas

Crystal S. Seldon, Lauren E. Colbert, William A. Hall, Sarah B. Fisher, David S. Yu, Jerome C. Landry

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Pancreatic cancer is one of the deadliest cancers with a very poor prognosis. Recently, there has been a significantincrease in research directed towards identifying potentialbiomarkers that can be used to diagnose and provideprognostic information for pancreatic cancer. Thesemarkers can be used clinically to optimize and personalizetherapy for individual patients. In this review, we focusedon 3 biomarkers involved in the DNA damage responsepathway and the necroptosis pathway: Chromodomainhelicase-DNA binding protein 5, chromodomain-helicase-DNA binding protein 7, and mixed lineage kinasedomain-like protein. The aim of this article is to reviewpresent literature provided for these biomarkers andcurrent studies in which their effectiveness as prognosticbiomarkers are analyzed in order to determine their futureuse as biomarkers in clinical medicine.

Original language	English (US)
Pages (from-to)	358-365
Number of pages	8
Journal	World Journal of Gastrointestinal Oncology
Volume	8
Issue number	4
DOIs	https://doi.org/10.4251/wjgo.v8.i4.358
State	Published - 2016
Externally published	Yes

Keywords

Biomarker
Chromodomain-helicase-dna binding protein 5
Chromodomain-helicase-dna binding protein 7
Mixed lineage kinase domain-like protein
Pancreatic adenocarcinoma

ASJC Scopus subject areas

Oncology
Gastroenterology

Access to Document

10.4251/wjgo.v8.i4.358

Cite this

Seldon, C. S., Colbert, L. E., Hall, W. A., Fisher, S. B., Yu, D. S., & Landry, J. C. (2016). Chromodomain-helicase-DNA binding protein 5, 7 and pronecrotic mixed lineage kinase domain-like protein serve as potential prognostic biomarkers in patients with resected pancreatic adenocarcinomas. World Journal of Gastrointestinal Oncology, 8(4), 358-365. https://doi.org/10.4251/wjgo.v8.i4.358

Chromodomain-helicase-DNA binding protein 5, 7 and pronecrotic mixed lineage kinase domain-like protein serve as potential prognostic biomarkers in patients with resected pancreatic adenocarcinomas. / Seldon, Crystal S.; Colbert, Lauren E.; Hall, William A. et al.
In: World Journal of Gastrointestinal Oncology, Vol. 8, No. 4, 2016, p. 358-365.

Research output: Contribution to journal › Article › peer-review

Seldon, CS, Colbert, LE, Hall, WA, Fisher, SB, Yu, DS & Landry, JC 2016, 'Chromodomain-helicase-DNA binding protein 5, 7 and pronecrotic mixed lineage kinase domain-like protein serve as potential prognostic biomarkers in patients with resected pancreatic adenocarcinomas', World Journal of Gastrointestinal Oncology, vol. 8, no. 4, pp. 358-365. https://doi.org/10.4251/wjgo.v8.i4.358

@article{de3dda097f1b430dac1d50beea756ca5,

title = "Chromodomain-helicase-DNA binding protein 5, 7 and pronecrotic mixed lineage kinase domain-like protein serve as potential prognostic biomarkers in patients with resected pancreatic adenocarcinomas",

abstract = "Pancreatic cancer is one of the deadliest cancers with a very poor prognosis. Recently, there has been a significantincrease in research directed towards identifying potentialbiomarkers that can be used to diagnose and provideprognostic information for pancreatic cancer. Thesemarkers can be used clinically to optimize and personalizetherapy for individual patients. In this review, we focusedon 3 biomarkers involved in the DNA damage responsepathway and the necroptosis pathway: Chromodomainhelicase-DNA binding protein 5, chromodomain-helicase-DNA binding protein 7, and mixed lineage kinasedomain-like protein. The aim of this article is to reviewpresent literature provided for these biomarkers andcurrent studies in which their effectiveness as prognosticbiomarkers are analyzed in order to determine their futureuse as biomarkers in clinical medicine.",

keywords = "Biomarker, Chromodomain-helicase-dna binding protein 5, Chromodomain-helicase-dna binding protein 7, Mixed lineage kinase domain-like protein, Pancreatic adenocarcinoma",

author = "Seldon, {Crystal S.} and Colbert, {Lauren E.} and Hall, {William A.} and Fisher, {Sarah B.} and Yu, {David S.} and Landry, {Jerome C.}",

year = "2016",

doi = "10.4251/wjgo.v8.i4.358",

language = "English (US)",

volume = "8",

pages = "358--365",

journal = "World Journal of Gastrointestinal Oncology",

issn = "1948-5204",

publisher = "Baishideng Publishing Group",

number = "4",

}

TY - JOUR

T1 - Chromodomain-helicase-DNA binding protein 5, 7 and pronecrotic mixed lineage kinase domain-like protein serve as potential prognostic biomarkers in patients with resected pancreatic adenocarcinomas

AU - Seldon, Crystal S.

AU - Colbert, Lauren E.

AU - Hall, William A.

AU - Fisher, Sarah B.

AU - Yu, David S.

AU - Landry, Jerome C.

PY - 2016

Y1 - 2016

N2 - Pancreatic cancer is one of the deadliest cancers with a very poor prognosis. Recently, there has been a significantincrease in research directed towards identifying potentialbiomarkers that can be used to diagnose and provideprognostic information for pancreatic cancer. Thesemarkers can be used clinically to optimize and personalizetherapy for individual patients. In this review, we focusedon 3 biomarkers involved in the DNA damage responsepathway and the necroptosis pathway: Chromodomainhelicase-DNA binding protein 5, chromodomain-helicase-DNA binding protein 7, and mixed lineage kinasedomain-like protein. The aim of this article is to reviewpresent literature provided for these biomarkers andcurrent studies in which their effectiveness as prognosticbiomarkers are analyzed in order to determine their futureuse as biomarkers in clinical medicine.

AB - Pancreatic cancer is one of the deadliest cancers with a very poor prognosis. Recently, there has been a significantincrease in research directed towards identifying potentialbiomarkers that can be used to diagnose and provideprognostic information for pancreatic cancer. Thesemarkers can be used clinically to optimize and personalizetherapy for individual patients. In this review, we focusedon 3 biomarkers involved in the DNA damage responsepathway and the necroptosis pathway: Chromodomainhelicase-DNA binding protein 5, chromodomain-helicase-DNA binding protein 7, and mixed lineage kinasedomain-like protein. The aim of this article is to reviewpresent literature provided for these biomarkers andcurrent studies in which their effectiveness as prognosticbiomarkers are analyzed in order to determine their futureuse as biomarkers in clinical medicine.

KW - Biomarker

KW - Chromodomain-helicase-dna binding protein 5

KW - Chromodomain-helicase-dna binding protein 7

KW - Mixed lineage kinase domain-like protein

KW - Pancreatic adenocarcinoma

UR - http://www.scopus.com/inward/record.url?scp=85052240056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052240056&partnerID=8YFLogxK

U2 - 10.4251/wjgo.v8.i4.358

DO - 10.4251/wjgo.v8.i4.358

M3 - Article

C2 - 27096031

AN - SCOPUS:85052240056

SN - 1948-5204

VL - 8

SP - 358

EP - 365

JO - World Journal of Gastrointestinal Oncology

JF - World Journal of Gastrointestinal Oncology

IS - 4

ER -

Chromodomain-helicase-DNA binding protein 5, 7 and pronecrotic mixed lineage kinase domain-like protein serve as potential prognostic biomarkers in patients with resected pancreatic adenocarcinomas

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this